Patients with combined dysadherin immunopositivity in over 50% of tumour cells and reduced E-cadherin immunopositivity survived significantly shorter than those with other combinations of dysadherin and E-cadherin immunopositivity (P=0.0043 and 0.0028, log-rank test for overall and recurrence-free survival rates, respectively; Figure 2E, F). Here, CDH1 is linked to neoplasm.